YMAB - Y-mAbs Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.02
+1.42 (+5.77%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close24.60
Open24.52
Bid16.59 x 800
Ask27.00 x 2900
Day's Range23.49 - 26.21
52 Week Range15.17 - 31.00
Volume230,905
Avg. Volume70,425
Market Cap889.72M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.50
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.50
Trade prices are not sourced from all markets
  • GlobeNewswire18 days ago

    Y-mAbs Therapeutics To Present At The H.C. Wainwright Global Life Sciences Conference in London

    NEW YORK, April 03, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • Have Insiders Been Buying Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares?
    Simply Wall St.22 days ago

    Have Insiders Been Buying Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunatel...

  • GlobeNewswirelast month

    Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights

    NEW YORK, March 22, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswirelast month

    Y-mAbs Therapeutics To Present At Cowen’s 39th Annual Health Care Conference

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced today that Dr. Claus Møller, MD, Ph.D., Chief Executive Officer of Y-mAbs Therapeutics will provide an overview and update on the company's business at Cowen’s 39th Annual Health Care Conference in Boston, Massachusetts. The presentation will take place on Tuesday, March 12, 2019, at 8:40 AM Eastern Daylight Time, and the presentation deck will be made available on the Company website at the time of presentation. Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.

  • GlobeNewswire2 months ago

    Y-mAbs Therapeutics to Present at PEGS Boston

    NEW YORK, Feb. 13, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • What Kind Of Investor Owns Most Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)?
    Simply Wall St.4 months ago

    What Kind Of Investor Owns Most Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)?

    A look at the shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...

  • GlobeNewswire4 months ago

    Y-mAbs Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Dec. 13, 2018 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire4 months ago

    Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the appointment of the molecular nuclear medicine executive, Dr. Gérard Ber, PhD to its board of directors, and the planned departure of Dr. Michael Buschle, PhD. The departure of Dr. Buschle and the appointment of Dr. Ber is effective December 11, 2018.

  • GlobeNewswire4 months ago

    Y-mAbs Therapeutics Announces FDA Clearance of IND for its Bispecific GD2 Antibody

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Investigational New Drug (“IND”) application for a humanized bispecific GD2 antibody. It is anticipated that a Phase 1/2 clinical trial will soon be initiated to begin screening patients with relapsed/refractory neuroblastoma, high grade osteosarcoma and other GD2(+) solid tumors, where patients have relapsed or refractory disease that is resistant to standard therapy.

  • GlobeNewswire5 months ago

    Y-mAbs Announces Third Quarter 2018 Financial Results and Recent Corporate Developments

    NEW YORK, Nov. 13, 2018 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire6 months ago

    Bispecific GD2 Antibody In Vivo Data to be Presented at ASH

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Jeong A Park from the Department of Pediatrics of Memorial Sloan-Kettering Cancer Center (MSK) will present preclinical data from the Company’s bispecific GD2 antibody in a poster presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA on December 3, 2018, at 9:00 PM Eastern. Bispecific GD2 antibodies were tested in solid tumors in preclinical models with T-cells and were shown to exert anti-tumor effect against GD2(+) tumor xenografts or PDX tumors.